Fax: +61-2-9385 0876
Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection†
Version of Record online: 29 JUL 2010
Copyright © 2010 American Association for the Study of Liver Diseases
Volume 52, Issue 4, pages 1216–1224, October 2010
How to Cite
Grebely, J., Petoumenos, K., Hellard, M., Matthews, G. V., Suppiah, V., Applegate, T., Yeung, B., Marks, P., Rawlinson, W., Lloyd, A. R., Booth, D., Kaldor, J. M., George, J. and Dore, G. J. (2010), Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology, 52: 1216–1224. doi: 10.1002/hep.23850
Potential conflict of interest: G.D., G.M., and J.K. have received research support from Roche Pharmaceuticals. G.D. is on the speaker's bureau for Roche Pharmaceuticals. G.D. and G.M. are members of advisory board for Roche Pharmaceuticals. G.D., P.M., and B.Y. have received travel grants from Roche Pharmaceuticals. G.D. is a consultant/advisor for Schering-Plough, Tibotec, and Abbott. J. Grebely is a member of an advisory board for Schering-Plough. G.M. is a consultant/advisor for Schering-Plough, Novartis, and Astellas.
- Issue online: 29 JUL 2010
- Version of Record online: 29 JUL 2010
- Manuscript Accepted: 6 JUL 2010
- Manuscript Received: 27 JUN 2010
- National Institutes of Health grant. Grant Number: RO1 DA 15999-01
- NCHECR is funded by the Australian Government Department of Health and Ageing and is affiliated with the Faculty of Medicine, UNSW
- Roche Pharmaceuticals supplied financial support for pegylated IFN-alfa-2a/ribavirin
- National Health and Medical Research Council Practitioner
- National Health and Medical Research Council Career Development Award and a VicHealth Senior Research Fellowship
- Canadian Institutes of Health Research and the National Canadian Research Training Program in Hepatitis C
- National Health and Medical Research Council Research Fellowship
Additional Supporting Information may be found in the online version of this article.
|HEP_23850_sm_suppfig1.tif||634K||Supporting Figure 1. Spontaneous HCV clearance among participants with genotyping at the SNPs rs8099917 (n=79) and rs12980275 (n=75) in the IL28B gene in the ATAHC study, excluding treated participants with an estimated duration of infection <26 weeks.|
|HEP_23850_sm_suppfig2.tif||732K||Supporting Figure 2. Sustained virological response among adherent participants with genotyping at the SNPs rs8099917 (n=54) and rs12980275 (n=57) in the IL28B gene in the ATAHC study.|
|HEP_23850_sm_supptab1.doc||74K||Supporting Table 1|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.